A comparison of APACHE II and CPIS scores for the prediction of 30-day mortality in patients with ventilator-associated pneumonia. (January 2015)

• Record Type: Journal Article
• Authors: Zhou, Xiao-Yu; Ben, Su-Qin; Chen, Hong-Lin; Ni, Song-Shi
• Is Part Of: International journal of infectious diseases. Volume 30(2015:Jan.)
• Page Start: 144
• Page End: 147
• Publication Date: 2015-01
• Subjects: Ventilator-associated pneumonia -- Mortality -- APACHE II -- CPIS; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2014.11.005
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: APACHE II was useful in predicting 30-day mortality in patients with ventilator-associated pneumonia (VAP) compared with CPIS. The CPIS did not have good discrimination and calibration for predicting 30-day mortality in patients with VAP. Summary: Objective: The aim of this study was to compare the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the Clinical Pulmonary Infection Score (CPIS) for the prediction of 30-day mortality in patients with ventilator-associated pneumonia (VAP). Methods: A single-center, prospective cohort study design was employed between January 1, 2010 and January 1, 2014. APACHE II and CPIS scores were determined on the day of VAP diagnosis. Discrimination was tested using receiver-operating characteristic (ROC) curves and the areas under the curve (AUC). Calibration was tested using the Hosmer–Lemeshow statistic. Results: Of 135 patients with VAP, 39 died; the 30-day mortality was 28.9%. APACHE II and CPIS scores were significantly higher in non-survivors compared to survivors (23.1 ± 4.8 vs. 16.7 ± 4.6, p < 0.001; 6.8 ± 1.3 vs. 6.2 ± 1.3, p = 0.016). APACHE II had excellent discrimination for predicting 30-day mortality in patients with VAP, with AUC 0.808 (95% confidence interval (CI) 0.704–0.912, p < 0.001). However, the CPIS score did not have discrimination power for predicting mortality, with AUC 0.612 (95% CI 0.485–0.739, p = 0.083). The Hosmer–Lemeshow statistic showed good goodness-of-fit for observed 30-day mortality and APACHE II expected mortality (Chi-square = 1.099, p = 0.785). However, CPIS expected 30-day mortality did not fit the observed mortality (Chi-square = 6.72, p = 0.004). Conclusions: These data suggest that APACHE II is useful for predicting 30-day mortality in patients with VAP, but that the CPIS does not have good discrimination and calibration for predicting mortality.